CN104434946A - Compound drug for external use for treating acne - Google Patents
Compound drug for external use for treating acne Download PDFInfo
- Publication number
- CN104434946A CN104434946A CN201410688787.5A CN201410688787A CN104434946A CN 104434946 A CN104434946 A CN 104434946A CN 201410688787 A CN201410688787 A CN 201410688787A CN 104434946 A CN104434946 A CN 104434946A
- Authority
- CN
- China
- Prior art keywords
- acne
- drug
- compound
- medicine
- compound drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a compound drug for external use for treating acne. The compound is characterized in that a substrate carrier of the compound drug comprises the following active ingredients: a non-steroidal anti-inflammatory drug, cimetidine and an antibacterial drug. The compound drug has the advantages that the three kinds of active ingredients can simultaneously act on a plurality links (anti-inflammation, antibiosis and reduction of sebum secretion) in the acne pathological process, so that the curative effect on acne, particularly on inflammatory acne, is improved; the compound drug is high in safety, free of irritant and free of anaphylaxis; the contained active ingredients are low in cost and easy to obtain, and the finished compound drug can be accepted by patients with acne.
Description
Technical field:
The present invention relates to a kind of externally used compound medicine of Acne treatment.
Background technology
Acne is commonly called as acne, comedo etc., and be sebaceous gland chronic disease, in youth of both sexes, sickness rate is very high, causes certain tired brain and pressure to patient.
Acne can be divided into polytype, and one is divided into inflammatory and non-inflammatory acne two class, the highest with acne sickness rate.
Pathogenesis of acne is multiple because have, and its pathological process relates generally to four aspects: 1. in body, Serum Testosterone Levels raises or relatively raises, and causes smegma hyperfunction; 2. too much sebum is beneficial to invasion and attack and the breeding of microorganism; 8. pilosebaceous duct dyskeratosis, causes acne to be formed; 4. the startup of inflammation, causes the inflammation that perifollicolar occurrence degree does not wait.
Medicine is the Main Means of Acne treatment, can oral or external, for reducing adverse effect based on external.Antibacterial and anti-inflammation drugs is mainly applied to acne; For non-inflammatory acne mainly with dissolving medicine for treating comedo.
Mostly be the folk prescription containing antimicrobial drug in the external used medicine of current Acne treatment, act on single, curative effect is not ideal enough; Antiinflammatory is the important means for the treatment of acne, though corticosteroids medicine has powerful antiinflammatory action, can cause agents area telangiectasis, erythema, state of an illness knock-on etc. after drug withdrawal, therefore be rarely used in the treatment of acne; Though the medicine dissolving acne is as obvious to non-inflammatory acne curative effect in tretinoin and derivant thereof, there is teratogenesis or the large shortcoming of zest, be only applicable to severe acne; Though also have many compound external-use preparations, all there is such or such problem.
Summary of the invention
The object of the invention is to: a kind of Acne treatment is provided, especially acne is had to the new external used medicine of good therapeutical effect.
The object of the present invention is achieved like this: in a kind of externally used compound medicine of Acne treatment, containing the active component disturbing the multiple pathology link of acne simultaneously, to improve its curative effect of medication.These active component comprise antiandrogen medicine, anti-inflammatory agent and antimicrobial drug.
The cimetidine in H2 receptor blocking agent selected by antiandrogen medicine.This product is the medicine for the treatment of taste-blindness rate disease, finds that it has antiandrogen effect, can stop testosterone and hair follicle receptors bind later, thus suppresses the secretion of sebaceous gland.Add this composition in this compound medicine, play the effect of effecting a permanent cure.
Antibacterials select the main pathogenic fungi of being correlated with to pathogenesis of acne such as propanoic acid Propiobacterium to have the medicine compared with high inhibition or killing action, example hydrochloric acid clindamycin, clindamycin phosphate, metronidazole, tinidazole, ornidazole etc., thus the infection link alleviating or eliminate morbidity.
Anti-inflammatory treatment we have suggested NSAID (non-steroidal anti-inflammatory drug), such medicine reduces the generation of inflammatory mediator prostaglandin by suppressing epoxidase and plays antiinflammatory action, all effective to Acute and chronic inflammation, especially significance is had more to the treatment of granulomatous suppression to acne.We, by after adding NSAID (non-steroidal anti-inflammatory drug) diclofenac sodium in this compound medicine, in clinical treatment observation, are surprised to find, and start to disappear in many l ~ 3 after medication of skin lesion day, total effective rate significantly improves, and presents quick-acting, efficient feature.Infer its reason, except the antiinflammatory action of diclofenac sodium itself, after cutaneous lesion hyperemia, edema extinction, be also conducive to the infiltration of other drug to deep tissue, thus curative effect improves.In addition, in antiinflammatory, diclofenac sodium and cimetidine can play synergism, because the latter can vasodilation caused by partial agonistic histamine and oozing out.
From the above mentioned, the invention has the advantages that: the active component containing cimetidine, antimicrobial drug and NSAID (non-steroidal anti-inflammatory drug) three kinds of Acne treatments in this compound preparation, play antiinflammatory, antibacterial and reduce the effect such as sebum secretion, to make therapeutical effect more comprehensively, deeply, curative effect is more satisfied simultaneously; This compound preparation nonirritant and anaphylaxis; Because material medicine is easy to get, and cheap,
Made finished medicines is bound to as vast patients with acne is accepted.
Detailed description of the invention:
Non-limiting exemplify certain embodiments involved in the present invention below.
EXAMPLE l:
The effective active composition of the present embodiment adopts diclofenac sodium 0.5%, Clindamycin Hydrochloride l%, cimetidine l%, and medium carrier adopts isopropyl alcohol, propylene glycol and distilled water, makes liniment.
Embodiment 2
The effective active composition of the present embodiment adopts diclofenac sodium l%, clindamycin phosphate l%, cimetidine 2%, and substrate is carried and done to adopt hexadecanol, vaseline, liquid paraffin, glyceryl monostearate, glycerol, triethanolamine and distillation, makes ointment.
Embodiment 3:
The effective active composition of the present embodiment adopts diclofenac sodium l%, ornidazole 2%, cimetidine 2%, and medium carrier adopts carbomer, isopropyl alcohol, propylene glycol, disodium edetate and distilled water, makes gel.
We suffer from the students (about 80 people) of acne to part, have carried out preliminary efficacy observation with the liniment of this compound external-use medicine, are reference substance with Cuo health king (clindamycin metronidazole liniment, Kuning Dianhong Pharmaceutical Co., Ltd. produces).Each coating 0.5 ~ 2ml, every day 2 times, continuous use 4 weeks.Result: test group effective percentage is 91.1%; Matched group effective percentage is 73.2%.Show this liniment have quick-acting, efficient, have no adverse reaction, without greasy feeling and the advantage such as easy to use.
Claims (5)
1. an externally used compound medicine for Acne treatment, is characterized in that: be made up of NSAID (non-steroidal anti-inflammatory drug), youngster's receptor blocking agent, antimicrobial drug three class effective active composition in this complex external medicine medium carrier.
2. the externally used compound medicine of Acne treatment according to claim l, it is characterized in that: containing NSAID (non-steroidal anti-inflammatory drug), its content (percentage by weight) is 0.5% ~ 2%.
3. the externally used compound medicine of Acne treatment according to claim l, it is characterized in that: containing youngster's receptor blocking agent, wherein cimetidine should be selected to be good, and its content (percentage by weight) is l% ~ 2%.
4. the externally used compound medicine of Acne treatment according to claim l, is characterized in that: containing antimicrobial drug: its content (percentage by weight) is 0.1% ~ 5%.
5. the externally used compound medicine of Acne treatment according to claim l, is characterized in that: after the effective active composition that it contains mixes with medium carrier, forms emulsifiable paste or gel or liniment or liniment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410688787.5A CN104434946A (en) | 2014-11-26 | 2014-11-26 | Compound drug for external use for treating acne |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410688787.5A CN104434946A (en) | 2014-11-26 | 2014-11-26 | Compound drug for external use for treating acne |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104434946A true CN104434946A (en) | 2015-03-25 |
Family
ID=52882209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410688787.5A Pending CN104434946A (en) | 2014-11-26 | 2014-11-26 | Compound drug for external use for treating acne |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104434946A (en) |
-
2014
- 2014-11-26 CN CN201410688787.5A patent/CN104434946A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8784852B2 (en) | Topical skin care composition | |
| CA1226224A (en) | Dermatological preparation containing asa | |
| JP2002512971A (en) | Topical substance mixture containing olive oil and honey | |
| RU2007118663A (en) | METHOD FOR ADAPALENE SUPPORT FOR SUPPORT THERAPY OF AN ACID CRUSH | |
| KR20110074513A (en) | Topical treatment of skin infection | |
| CN112587446A (en) | Composition for treating acne and preparation method and application thereof | |
| US20140199413A1 (en) | Melatonin and an antimicrobial or antibacterial agent for the treatment of acne | |
| JP2010502700A (en) | Drugs for treating acne, drugs for recovering symptoms of aging and sunburn, and methods using the same | |
| JP2015081244A (en) | Acne treating pharmaceutical composition | |
| US20200030398A1 (en) | Skin care composition | |
| CN104434946A (en) | Compound drug for external use for treating acne | |
| EP2588095B1 (en) | Composition for the treatment of acne vulgaris | |
| CN103285397A (en) | External compound medicine for treating acne | |
| CA2443939A1 (en) | Dermatological composition comprising nicotinic acid or an amide, and a sphingoid base | |
| WO2017020036A1 (en) | Composition and related methods for treatment of pilosebaceous diseases | |
| CA2540859A1 (en) | Topical compositions comprising telmesteine for treating dermatological disorders | |
| CN101766731B (en) | Tea polyphenol acne resistant external preparation | |
| US10071052B2 (en) | Method for the prevention and treatment of acne | |
| CN1528327A (en) | Complex external medicine speical for acne and preparing method thereof | |
| CN106389789A (en) | Western medicine composition for preventing and treating acne and preparation method of western medicine composition | |
| JP2023077696A (en) | Acne vulgaris improver | |
| KR20150057014A (en) | Cosmetic composition containing extracts of Curcuma longa Linne for controlling anti-acne or anti-comedone | |
| CN101156899A (en) | New medicament usage of paeonol unction | |
| CN105663098A (en) | External liniment for treating acnes | |
| Zeichner | Cosmeceuticals for the treatment of acne vulgaris |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150325 |